Flibanserin [167933-07-5]

Chemodex

Flibanserin [167933-07-5]

10

6.1

167933-07-5

Research Use Only

>98%

Danger,Excepted quantity

C20H21F3N4O

390.4

Chemical. CAS: 167933-07-5. Formula: C20H21F3N4O. MW: 390.4. Synthetic. Flibanserin is a full agonist of the serotonin 5-HT1A receptor and an antagonist of 5-HT2A (Ki=1nm and 49nM, respectively). It also binds to dopamine D4 receptors with Ki values ranging from 4-24nM, but demonstrates no affinity for the other 5-HT subtypes or other neurotransmitter receptors. Multifunctional serotonergic ligands like flibanserin that can enhance downstream release of dopamine and norepinephrine while concomitantly reducing serotonin release in the brain circuits that mediate symptoms of reduced sexual interest and desire, are being studied clinically for therapeutic potential to improve sexual functioning. Flibanserin was investigated as a novel, non-hormonal treatment for pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD). Flibanserin was also found to reduce L-DOPA-induced dyskinesia in a model of Parkinsons Disease. - Flibanserin is a full agonist of the serotonin 5-HT1A receptor and an antagonist of 5-HT2A (Ki=1nm and 49nM, respectively). It also binds to dopamine D4 receptors with Ki values ranging from 4-24nM, but demonstrates no affinity for the other 5-HT subtypes or other neurotransmitter receptors. Multifunctional serotonergic ligands like flibanserin that can enhance downstream release of dopamine and norepinephrine while concomitantly reducing serotonin release in the brain circuits that mediate symptoms of reduced sexual interest and desire, are being studied clinically for therapeutic potential to improve sexual functioning. Flibanserin was investigated as a novel, non-hormonal treatment for pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD). Flibanserin was also found to reduce L-DOPA-induced dyskinesia in a model of Parkinsons Disease.

O=C1NC2=CC=CC=C2N1CCN3CCN(C4=CC=CC(C(F)(F)F)=C4)CC3

2°C to 8°C

2810

12352200